{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-025442","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.465664+00:00","generated_at":"2026-06-21T15:52:20.783613+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Athira Pharma amends bylaws for SEC Rule 14a-19 compliance and advance notice updates","bullets":["Board approved amended and restated bylaws effective November 15, 2022.","Changes comply with new SEC Rule 14a-19 (universal proxy) and enhance advance notice for stockholder proposals and nominations.","Bylaws updated for recent Delaware General Corporation Law amendments on stockholder meetings.","Modifications to officer appointments, board committee procedures, and forum selection clause."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-025442","json":"https://secwatch.observer/filing/0000950170-22-025442.json","markdown":"https://secwatch.observer/filing/0000950170-22-025442.md","text":"https://secwatch.observer/filing/0000950170-22-025442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017022025442/0000950170-22-025442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017022025442/atha-20221115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:52:20.783613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0be66a30ac1e19e2ffaf4a807f3a13802040fbcc","claim":"LeonaBio, Inc.: Amended and restated bylaws to comply with Rule 14a-19 and enhance advance notice procedures for stockholder proposals and nominations, along with other updates (effective 2022-11-15).","evidence_excerpt":"On November 15, 2022, the board of directors (the “Board”) of Athira Pharma, Inc. (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”) of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000095017022025442/0000950170-22-025442-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-11-15"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}